SCHEMBL6488558

SCHEMBL6488558

Cc1ccc(C(=O)Nc2ccc(F)c([N+](=O)[O-])c2)c(-c2ccc(C(F)(F)F)cc2)c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 10/20 0.50
RECQL P46063 1/20 0.50
TRPV1 Q8NER1 1/20 0.48
MEN1 O00255 6/20 0.48
KMT2A Q03164 6/20 0.48
HTT P42858 2/20 0.48
MAPT P10636 8/20 0.46
ALDH1A1 P00352 3/20 0.46
POLB P06746 1/20 0.46
APOB P04114 2/20 0.46
MTTP P55157 2/20 0.46
MCL1 Q07820 1/20 0.45
P2RX1 P51575 2/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
MAPK1 P28482 3/20 0.44
RAB9A P51151 2/20 0.44
NPC1 O15118 1/20 0.44
ATM Q13315 1/20 0.44
TDP1 Q9NUW8 1/20 0.44
TP53 P04637 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6801792 0.87 TP53 (0.56) LMNATRPV1MEN1KMT2AHTT
SCHEMBL6496388 0.85 ABCG2 (0.56) TRPV1MEN1KMT2AHTTMAPT
SCHEMBL6638787 0.80 LMNA (0.55) LMNATRPV1MEN1KMT2AHTT
SCHEMBL6490383 0.79 PTGS1 (0.58) LMNATRPV1HTTAPOBMTTP
SCHEMBL6490917 0.78 TRPV1 (0.47) LMNATRPV1MEN1KMT2AMAPT
SCHEMBL6803739 0.78 SMO (0.48) LMNATRPV1MEN1KMT2AMAPT
SCHEMBL6500905 0.78 TRPV1 (0.50) LMNATRPV1HTTAPOBMTTP
SCHEMBL6640573 0.77 LMNA (0.52) LMNARECQLMEN1KMT2AHTT
SCHEMBL6687830 0.76 P2RX1 (0.48) LMNATRPV1HTTAPOBMTTP
SCHEMBL6794883 0.76 P2RX1 (0.56) LMNATRPV1MAPTALDH1A1APOB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050038035-A1 Heterocyclic amide compounds as apolipoprotein b inhibitors DAISO CO., LTD. (JP) 2005-02-17 US disclosed
US-20040157866-A1 Amide compounds FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-08-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040157866-A1 Amide compounds APOB, NR1H2, NR1H3 LMNA 956/4885RECQL 4038/4885TRPV1 2399/4885
US-20050038035-A1 Heterocyclic amide compounds as apolipoprotein b inhibitors APOB, APOL1, CTRB2 LMNA 629/4885RECQL 3329/4885TRPV1 2245/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.